AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

Obesity caused by a lifestyle of moving less and eating more is a prime factor contributing to Type 2 diabetes. Is the answer ...

The pharmaceutical company Viking has recently become one of the most volatile stocks on Wall Street due to the announcement ...

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

The U.K.-based company released the data at Obesity Week, an event organized by the Obesity ... after investors were underwhelmed by early data from a trial of a weight-loss pill.

AstraZeneca’s new obesity pill, licensed from China’s Eccogene last year, has shown initial promise in early-stage trials.

Cellular's schizophrenia drug meeting trial goals, Britain's new mpox variant detection, proposed UK smoking bans, challenges in weight-loss medication access, CVS Health's strategy adaptation, South ...

While expected and seen as largely incremental, Jefferies analyst Peter Welford in a Tuesday note to investors said the detailed data for three early-stage assets support moving them into Phase IIb ...

The obesity treatment study also produced effects ... Capsules containing screened donor feces are ingested as a pill that dissolves in the gut, introducing viruses and a variety of beneficial ...